Evaluation of drug efficacy

Before a drug enters the clinical research phase, it requires evaluation of its biological activity and pharmacokinetics through various techniques and methods. Traditionally, assessing drug toxicity in preclinical stages has been challenging due to the limited availability of human pathological functional cells, especially those in the early stages of pathology. As a result, preclinical tests often rely on experimental animal models, cancer cell lines, or a small number of human primary cells. However, these experimental models often diverge significantly from the actual physiological conditions of the human body, contributing to the high failure rate of new drug development during clinical trials and resulting in the phenomenon of substantial investment with low output in drug research and development.

Shownin Biotechnologies Co., Ltd. has now achieved the capability to produce a substantial quantity of disease-specific and normal induced pluripotent stem cells (hiPSC) with consistent quality. This includes iPSC cell lines for diseases such as Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), among others. Researchers can leverage these disease-specific iPSC cell lines to derive functional cells for effective testing of disease-related drug efficacy, facilitating the identification of candidate drugs and their effective dosage ranges in the treatment of various diseases。